Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.

Chromocell Therapeutics Corporation

Chromocell is a life sciences company which improves consumer products and patient lives through breakthrough science and technologies. Chromocell is focused on the discovery and development of therapeutics and flavors through the use of pioneering Chromovert® technology. Chromovert technology enables Chromocell to use rare cells ideally suited for effective high-throughput screening. Chromocell’s therapeutics pipeline is currently focused on analgesics and rare diseases, where Chromovert technology has proven highly effective in the rapid identification of potential new drug candidates. In our flavors and nutrition business, Chromocell works with global consumer goods companies to discover and develop flavor ingredients and natural taste enhancers. The technology is applicable to all areas of taste sensations as well as aroma and fragrance enhancer discovery.

	Dec '21	Dec '22	Dec '23
net income	-595.39K -	-2.46M 312.94%	-7.38M 200.20%
depreciation and amortization
deferred income tax
stock based compensation		110.15K -	3.96M 3,494.29%
change in working capital	-755.83K -	640.86K 184.79%	2.05M 220.05%
accounts receivables
inventory
accounts payables	-827.70K -	413.60K 149.97%	1.63M 293.37%
other working capital	71.87K -	227.26K 216.20%	424.07K 86.60%
other non cash items	585.91K -	-163.03K 127.82%	2.72M 1,769.47%
net cash provided by operating activities	-1.59M -	-1.57M 1.62%	-981.03K 37.40%
investments in property plant and equipment
acquisitions net
purchases of investments
sales maturities of investments
other investing activites
net cash used for investing activites
debt repayment	-1.10M -	-400K 63.63%	-766.94K 91.73%
common stock issued			255.41K -
common stock repurchased
dividends paid
other financing activites	1.59M -	1.22M 23.28%	1.02M 16.35%
net cash used provided by financing activities	1.59M -	1.62M 1.83%	1.02M 36.98%
effect of forex changes on cash
net change in cash		55.07K -	41.32K 24.98%
cash at beginning of period			55.07K -
cash at end of period		55.07K -	96.39K 75.02%
operating cash flow	-1.59M -	-1.57M 1.62%	-981.03K 37.40%
capital expenditure
free cash flow	-1.59M -	-1.57M 1.62%	-981.03K 37.40%

COM:CHROMOCELL

Chromocell

Last Close

0.63

22/11 20:59

Market Cap

3.88M

Beta: -

Volume Today

84.03K

Avg: -

Preview